Treasury Buyback Bonanza Sends Quant Funds into Turmoil and Catapults Moderna

The U.S. Treasury’s sudden expansion of its equity buyback program triggered market turbulence, while Moderna’s shares surged by 30%.

Treasury Buyback Surge: A Rapid Recoil

■In 2024, the Treasury expanded its buyback program to $200 billion.

■This injected liquidity into the market and lowered interest rates by 0.25%.

■The bulk of purchases targeted the technology and healthcare sectors.

Quant Funds in Shock

■High‑frequency trading algorithms recorded 5‑minute spikes in volatility.

■Portfolio rebalancing involved selling high‑risk assets.

■The result was a 3% decline in index‑fund performance.

Moderna’s Meteoric Rise

■Share price jumped from $150 to $195.

■The company’s new mRNA vaccine pipeline bolstered investor confidence.

■Analysts raised 2025 earnings guidance to $10 per share.

Broader Market Implications

■Markets closed up 0.8% on the day.

■Investors reassessed risk appetite.

■Central banks are increasingly considering policy‑rate revisions.

Rapid exits by quant funds dampen liquidity, while Treasury buybacks and Moderna’s robust performance reshape risk tolerance. This complex dynamic calls for a re‑orientation of mid‑term strategies focused on technology and healthcare.